SCHEMBL2197291

SCHEMBL2197291

Brc1ccc(CN(I)I)cc1.COc1cccc(Cn2ccn(C)c2=[Pt])c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPO P22079 3/20 0.52
MAPT P10636 5/20 0.46
TP53 P04637 4/20 0.46
LMNA P02545 2/20 0.46
MAOB P27338 1/20 0.40
HTT P42858 1/20 0.40
CMA1 P23946 1/20 0.38
TSHR P16473 2/20 0.38
ALOX15 P16050 1/20 0.38
SIGMAR1 Q99720 1/20 0.37
POLB P06746 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2194627 0.91 LPO (0.56) LPOMAPTTP53LMNACMA1
SCHEMBL2196516 0.91 LPO (0.53) LPOMAPTTP53LMNAMAOB
SCHEMBL2195305 0.90 LPO (0.52) LPOMAPTTP53LMNAMAOB
SCHEMBL2194970 0.90 LPO (0.52) LPOMAPTTP53LMNAHTT
SCHEMBL2195985 0.88 MAPT (0.38) LPOMAPTTP53LMNAHTT
SCHEMBL2197428 0.87 LPO (0.49) LPOMAPTTP53LMNACMA1
SCHEMBL2198406 0.87 LPO (0.51) LPOMAPTTP53LMNACMA1
SCHEMBL2194395 0.85 MAPK10 (0.38) MAPTTP53LMNAHTTTSHR
SCHEMBL2192896 0.82 MAPT (0.46) MAPTTP53LMNAMEN1KMT2A
SCHEMBL2194976 0.82 SIGMAR1 (0.44) LPOMAPTTP53LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 LPO 962/4885MAPT 4712/4885TP53 1327/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 LPO 962/4885MAPT 4712/4885TP53 1327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.